NCT04106856View on ClinicalTrials.gov

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 8, 2019

Primary Completion Date

December 6, 2024

Study Completion Date

August 8, 2026

Conditions
Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaLocally Advanced Unresectable Pancreatic AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8Stage IIB Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8
Interventions
RADIATION

Hypofractionated Radiation Therapy

Undergo hypofractionated radiation therapy

DRUG

Losartan

Given PO

DRUG

Losartan Potassium

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Utah

OTHER

NCT04106856 - Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER) | Biotech Hunter | Biotech Hunter